Prognostic factors in metastatic XXXX .

@entity1 @entity66 @entity5 @entity900 @entity160 @entity358
OBJECTIVE: To determine predictors of prognostic significance for @entity1 with nonseminomatous @entity5 (NSTC) who have advanced disease at the time of presentation. DESIGN: A chart review with a mean @entity1 follow-up of 5.5 years (range from 0.75 to 13 years). SETTING: University hospitals in Halifax. @entity1 : All @entity1 with NSTC, stages II-B, II-C and III. @entity1 were excluded if the follow-up status at the time the study closed could not be determined. Thirty-three @entity1 were included in the study. Current @entity1 status was determined from the clinical charts and personal communication with the @entity1 or their physicians. INTERVENTIONS: All @entity1 received @entity900 -based chemotherapy. The extent of the disease was assessed by chest radiography or lung tomography, bone scanning, abdominal computed tomography or lymphangiography. MAIN OUTCOME MEASURES: Correlation between levels of beta- @entity1 chorionic gonadotropin (BHCG) and @entity160 ( @entity160 ), comparison of duration of symptoms before initial treatment, response to treatment and survival, and relationship between stage, @entity5 volume and survival. RESULTS: The 3-year overall survival rate was 76%. Seven of 18 @entity1 with symptoms for more than 16 weeks died of disease (p < 0.01). Overall complete response was seen in 27 of 33 @entity1 . All initial nonresponders died. A survival rate of 93% was seen among initial complete responders (p < 0.01). All seven @entity1 with persistent elevation of BHCG levels (p < 0.001) and the two @entity1 with persistent elevation of @entity160 levels (p < 0.01) after the second course of chemotherapy died. CONCLUSIONS: A symptomatic interval of more than 16 weeks, poor response to initial treatment, @entity66 , @entity358 and persistently elevated levels of BHCG and @entity160 were all indicators of poor prognosis.
